LAVA Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Rhea-AI Summary

LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company, announced that its CEO Stephen Hurly will present at the H.C. Wainwright 24th Annual Global Investment Conference. The virtual presentation is scheduled for September 12, 2022, and will be available for on-demand viewing starting at 7:00 a.m. EDT. Investors can access the webcast through the investor relations section on LAVA Therapeutics' website, where a replay will be available for 90 days.

The company is focused on developing bispecific gamma delta T cell engagers through its proprietary Gammabody™ platform.

UTRECHT, The Netherlands and PHILADELPHIA, Sept. 07, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical stage immuno-oncology company focused on developing its proprietary Gammabody™ platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced that Stephen Hurly, president and chief executive officer of LAVA Therapeutics, will present in a virtual format at the H.C. Wainwright 24^th Annual Global Investment Conference being held virtually and in New York City.

Presentation Details
Format: Virtual Corporate Presentation
Date: Monday, September 12, 2022
Time: Available for on-demand viewing at 7:00 a.m. EDT

A webcast of the presentation can be accessed under the "Events" tab on the investor relations section of the LAVA Therapeutics website at: https://ir.lavatherapeutics.com/news-events/events. A replay will be archived for 90 days following the presentation date.

About LAVA Therapeutics
LAVA Therapeutics N.V. is a clinical stage immuno-oncology company utilizing its proprietary Gammabody™ platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid and hematologic malignancies. The Company utilizes bispecific antibodies engineered to selectively kill cancer cells by triggering Vγ9Vδ2 (Vgamma9 Vdelta2) T cell antitumor effector functions upon cross-linking to tumor-associated antigens. LAVA-051, the Company’s lead candidate for the treatment of multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia, is enrolling patients in a Phase 1/2a clinical study (NCT04887259). A Phase 1/2a clinical study to evaluate LAVA-1207 in patients with metastatic castration-resistant prostate cancer (mCRPC) is also enrolling (NCT05369000). For more information, please visit www.lavatherapeutics.com, and follow us on LinkedIn, Twitter and YouTube.

CONTACTS
Investor Relations
ir@lavatherapeutics.com

Argot Partners (IR/Media)
212-600-1902
lava@argotpartners.com

FAQ

When will Stephen Hurly present at the H.C. Wainwright Conference for LAVA Therapeutics (LVTX)?

Stephen Hurly will present on September 12, 2022.

How can I access LAVA Therapeutics' presentation at the investment conference?

The presentation can be accessed on-demand starting at 7:00 a.m. EDT on the company's investor relations website.

What is the focus of LAVA Therapeutics in their clinical studies?

LAVA Therapeutics focuses on developing bispecific gamma delta T cell engagers for treating solid and hematologic malignancies.

What is the status of LAVA-051 in clinical trials?

LAVA-051 is currently enrolling patients in a Phase 1/2a clinical study.

Where can I find more information about LAVA Therapeutics and its products?

More information is available on LAVA Therapeutics' official website.